Group 1 - The core point of the article highlights the performance of the China Europe Medical Innovation Stock C fund, which has shown a net value of 1.2838 yuan, reflecting a growth of 1.42% [1] - The fund's one-month return is 8.30%, ranking 36 out of 1025 in its category, while its six-month return is 22.03%, ranking 30 out of 987 [1] - Year-to-date, the fund has achieved a return of 27.56%, ranking 31 out of 999 in its category [1] Group 2 - The top ten holdings of the China Europe Medical Innovation Stock C fund account for a total of 75.62%, with the largest positions in WuXi AppTec (10.35%), Kelun-Biotech (10.15%), and WuXi Biologics (9.82%) [1] - The fund was established on February 28, 2019, and as of March 31, 2025, it has a total scale of 3.524 billion yuan, managed by fund manager Ge Lan [1] Group 3 - Ge Lan, the fund manager, holds a PhD in Biomedical Engineering from Northwestern University and has extensive experience in the investment management field, having worked with various funds since joining China Europe Fund Management in October 2014 [2]
6月3日中欧医疗创新股票C净值增长1.42%，今年来累计上涨27.56%
Sou Hu Cai Jing·2025-06-03 12:30